It's Probably Less Likely That ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Will See A Huge Pay Rise This Year [Yahoo! Finance]
ACADIA Pharmaceuticals Inc. (ACAD)
Last acadia pharmaceuticals inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.acadia-pharm.com/phoenix.zhtml?c=125180&p=irol-irhome
Company Research
Source: Yahoo! Finance
The overall pay is comparable to the industry average ACADIA Pharmaceuticals' three-year loss to shareholders was 27% while its EPS grew by 40% over the past three years In the past three years, the share price of ACADIA Pharmaceuticals Inc. NASDAQ:ACAD ) has struggled to grow and now shareholders are sitting on a loss. However, what is unusual is that EPS growth has been positive, suggesting that the share price has diverged from fundamentals. The AGM coming up on the 29th of May could be an opportunity for shareholders to bring these concerns to the board's attention. They could also influence management through voting on resolutions such as executive remuneration. Here's our take on why we think shareholders may want to be cautious of approving a raise for the CEO at the moment. Check out our latest analysis for ACADIA Pharmaceuticals Comparing ACADIA Pharmaceuticals Inc.'s CEO Compensation With The Industry According to our data, ACADIA Pharmaceuticals Inc. has a market
Show less
Read more
Impact Snapshot
Event Time:
ACAD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACAD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACAD alerts
High impacting ACADIA Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
ACAD
News
- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $29.00 price target on the stock.MarketBeat
- Why Is ACADIA Pharmaceuticals Inc (ACAD) One of the Best Debt Free Halal Stocks According to Hedge Funds? [Yahoo! Finance]Yahoo! Finance
- Acadia Pharmaceuticals Presents DAYBUE™ (trofinetide) Real-World Evidence and Additional Data in Rett Syndrome at the 2024 International Rett Syndrome Foundation (IRSF) Annual Scientific MeetingBusiness Wire
- Acadia Pharmaceuticals: Bullish On Nuplazid And Daybue Driven Growth In CNS Treatments [Seeking Alpha]Seeking Alpha
- Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome [Yahoo! Finance]Yahoo! Finance
ACAD
Earnings
- 5/8/24 - Beat
ACAD
Sec Filings
- 6/11/24 - Form 4
- 5/31/24 - Form 4
- 5/31/24 - Form 4
- ACAD's page on the SEC website